IngredientesAllicin (diallylthiosulfinate) is a defence molecule from garlic (Allium sativum L.) with a broad range of biological activities. Its molecular formula is C6H10OS2, and its synonyms include diallyl thiosulfinate, thio-2-propene-1-sulfinic acid S-allyl ester, and allylthiosulphinic acid allyl ester, with a molecular weight of 162.3 g/mol. Allicin is an oily, slightly yellow liquid. It is a thioester of a sulfinic acid, also known as allyl thiosulfinate, and features the thiosulfinate functional group R-S(O)-S-R.
The volatile organic sulfur compound allicin is produced as a defense substance when garlic (Allium sativum) tissues are damaged, for example by the activities of pathogens or pests. Allicin gives crushed garlic its characteristic odor, is membrane permeable and readily taken up by exposed cells. It is a reactive thiol-trapping sulfur compound that S-thioallylates accessible cysteine residues in proteins and low molecular weight thiols including the cellular redox buffer glutathione (GSH) in eukaryotes and Gram-negative bacteria, as well as bacillithiol (BSH) in Gram-positive firmicutes.
The sulfur-containing compound allicin is produced in damaged tissue of garlic (Allium sativum), ramsons (Allium ursinum), and hooker chives (Allium hookeri) and gives these plants their typical odours. Garlic is by far the most concentrated source of allicin, with lesser quantities found in onions, leeks, ramps, shallots, and scallions.
Allicin is produced upon tissue damage from the non-proteinogenic amino acid alliin (S-allylcysteine sulfoxide) in a reaction that is catalyzed by the enzyme alliinase. The allyl thiosulfinates, of which allicin is the most abundant and most studied member, are enzymatic products of alliin and alliinase. They are rapidly formed when raw garlic cloves undergo cell rupture or when dried and pulverized cloves (garlic powder) become wet.
Garlic supplements are typically provided as garlic powder in capsule form in doses equivalent to 1–2 grams of fresh raw garlic, either with or without an enteric coating. Some are standardized by allicin content. Aged garlic, whole-pickled garlic, and black garlic use ethanol, acid, and low heat, respectively, sustained over long periods to transform garlic into an extract with dramatically different smell and flavor. These preparations result in a much lower allicin content. In aged garlic products, the alliin converts to other sulfur compounds; they provide larger amounts of other sulfur derivatives such as γ-glutamyl-S-allylcysteine (GSAC) and S-allylcysteine (SAC), which show similar antioxidant effects to allicin.
Allicin (diallyl-thiosulfinate), the most biologically active compound of garlic, was discovered in 1944, and is noted for its potent antimicrobial activity. The isolation of allicin in 1944 enabled the development of standardized garlic extracts and supplements.
Crushed fresh garlic cloves generate antibacterial activity and chemically detectable allicin, and both declined on a daily basis in aqueous and ethanolic solutions at room temperature, showing biological and chemical half-lives of about 6 and 11 days, respectively. Allicin was more stable in 20% alcohol than in water, but surprisingly unstable in vegetable oil, with an activity half-life of 0.8 hours, as estimated from its antibacterial activity toward Escherichia coli. Allicin is unstable and quickly changes into a series of other sulfur-containing compounds such as diallyl disulfide.
Traditionally, the medical properties of garlic were recognized as early as 3000 BC. Its use in Ayurvedic Medicine and ancient Chinese Medicine was witnessed over 5000 and 3000 years ago, respectively. Garlic use as a prophylactic agent for heart diseases was reported in Africa over 3500 years ago in ancient Egyptian Codex Ebers.
Interest in the potential benefits of garlic was noted in records found in Egyptian pyramids and ancient Greek temples, as well as in ancient texts — including medical literature — from China, Egypt, Greece, India, Israel, and Rome, in which its use was prescribed.
The Ebers Papyrus and the "magical papyri" precisely mention the use of extracts from garlic for medicinal purposes; the first-century BC Roman poet Virgil highlighted their use in treating snake bites, and the famous Greek physician Hippocrates described their efficacy in treating pneumonia and in wound healing in his Corpus Hippocraticum.
Throughout history, garlic has been prepared and utilized in diverse forms — fresh, cooked, crushed, and infused in liquids such as wine — with each method enhancing its culinary and medicinal properties. In ancient Egypt, garlic was consumed raw by laborers to boost strength and endurance. The Greeks and Romans often crushed garlic to release its allicin compound, believed to possess significant health benefits, and mixed it with wine to create medicinal tinctures for treating digestive disorders and infections.
The Avesta, a collection of Zoroastrian holy literature most effectively compiled in the sixth century BC, contains some of the oldest references to this therapeutic herb. There is some evidence that athletes were given garlic to enhance strength during the first Olympics in Greece. Garlic was suggested to be used in traditional Chinese and Indian medicine to treat leprosy, aid digestion, and prevent parasite infestation.
One of the traditional Chinese medical treatments for intestinal diseases is an alcoholic extract of crushed garlic cloves. Galen, writing in the second century, eulogized garlic as the "rustic's theriac" (cure-all). In the 19th century, Louis Pasteur observed that garlic exhibited antibacterial properties, laying the groundwork for modern scientific investigation.
Several bioactive compounds from garlic, including allicin, allyl sulphides, alliin, ajoenes, and 1,2-vinyldithiin, have therapeutic effects as antioxidants, anti-inflammatory, cardioprotective, antimicrobial, anticancer, and immunomodulatory agents. Among these, allicin is the primary and most studied active compound.
Modern pharmacological research has demonstrated that sulfur-containing compounds such as allicin, diallyl disulfide (DDS), diallyl trisulfide (DTS), and S-allyl-L-cysteine (SAC) constitute the main components of garlic. Considerable evidence suggests that the allyl thiosulfinates, or their spontaneous transformation compounds (allyl polysulfides), or their common metabolite (allyl methyl sulfide, AMS), are responsible for most of the lipid-lowering, antioxidant, anti-atherosclerotic, and anticancer effects of whole garlic, as observed in animals and humans.
Being a thiosulfinate, allicin is a reactive sulfur species (RSS) and undergoes a redox-reaction with thiol groups in glutathione and proteins that is thought to be essential for its biological activity. Allicin is physiologically active in microbial, plant, and mammalian cells.
Allicin undergoes a thiol-disulfide type exchange reaction with available thiol groups, specifically with thiolate ions. In contrast to a standard thiol-disulfide exchange reaction, a molecule of water is generated from the thiosulfinate oxygen atom. The mixed disulfide formed can enter into further standard exchange reactions with fresh thiols, and a redox cycling cascade can ensue driven by various catalytic enzymes such as thioredoxins and glutaredoxins. Thus, the effects of allicin on cellular thiol homeostasis of proteins and cellular redox buffers, such as glutathione, can be profound.
Research indicates that the mode of action of allicin is a combination of a decrease of glutathione levels, unfolding stress, and inactivation of crucial metabolic enzymes through S-allylmercapto modification of cysteines. A proteome-wide investigation in Escherichia coli was performed to identify the proteins oxidized by allicin exposure. After cells were treated with 0.79 mM allicin, 73 S-thioallylated proteins were identified, including some essential enzymes of primary metabolism.
The main antimicrobial effect of allicin has been reported to be due to its chemical reaction with thiol groups present in the main enzymes of microbial metabolism, such as succinate dehydrogenase, alcohol dehydrogenase, thioredoxin reductase, and ureases, via thiol-disulfide exchange reaction. The antimicrobial effects are related to the ability of allicin to strongly inhibit thiol-containing enzymes such as cysteine proteinases, alcohol dehydrogenases, and thioredoxin reductases. In addition, allicin can increase the activity of Cu2+, which promotes antimicrobial activity, and allicin works by accelerating the production of endogenous reactive oxygen species (ROS).
Allicin is hydrophobic in nature and can efficiently cross cellular membranes, behaving as a reactive sulfur species (RSS) inside cells. It is a physiologically active molecule with the ability to oxidise the thiol groups of glutathione and between cysteine residues in proteins. Allicin inhibits the P38 and JNK pathways and the expression of NF-ÎşB, which explains the potential anti-inflammatory mechanisms of allicin.
Proposed pathophysiologies of allicin's cardiovascular effects include vasodilation via nitric oxide (NO) release, enhanced endothelial function, antioxidant properties, inhibition of angiotensin-converting enzyme (ACE) activity, sodium and water excretion, and anti-inflammatory effects. Allicin is probably responsible for inhibiting β-hydroxy β-methylglutaryl-CoA (HMG-CoA), and thus lowering total cholesterol and LDL while increasing HDL. Cardiac hypertrophy is limited by allicin's ability to control brain natriuretic peptide (BNP) and inhibit markers responsible for myocyte enlargement. Allicin also blocks reactive oxygen species (ROS), which support cardiac hypertrophy.
Allicin shows dose-dependent antimicrobial activity. At higher doses in eukaryotes, allicin can induce apoptosis or necrosis, whereas lower, biocompatible amounts can modulate the activity of redox-sensitive proteins and affect cellular signaling.
In a dose-dependent manner, allicin can inhibit the proliferation of both bacteria and fungi or kill cells outright, including antibiotic-resistant strains like methicillin-resistant Staphylococcus aureus (MRSA). Allicin has been investigated for an extensive range of medicinal applications including the treatment of bacterial infections. Select Gram-positive pathogens including MRSA and Bacillus anthracis (anthrax) exhibit susceptibility to allicin at clinically-relevant minimum inhibitory concentrations. In addition, synergism with vancomycin (VAN) has been reported for VAN-resistant Enterococcus (VRE).
Allicin can inhibit the growth of Mycobacterium tuberculosis, Escherichia coli, Trichosporon asahii, Pseudomonas aeruginosa, Salmonella Typhimurium, and Trichophyton rubrum. Numerous studies have shown that allicin is a strong natural antimicrobial substance. However, the majority of this evidence is derived from in vitro studies, and its translation to clinical settings requires careful evaluation of the effective concentrations achieved in vivo.
When used in combination with antibiotics or antifungals, allicin enhanced the antimicrobial activities of these substances and improved the antimicrobial efficacy. Evidence strength: Largely in vitro and animal; clinical human evidence is very limited.
Numerous studies have demonstrated allicin's remarkable antifungal activity against various clinically important fungal species, including Candida spp., Cryptococcus spp., Aspergillus spp., Trichophyton spp., and others. The minimal inhibitory concentration (MIC) of allicin against Cryptococcus neoformans H99 was 2 ÎĽg/ml, which is comparable to fluconazole (1 ÎĽg/ml). Allicin exhibited effective antifungal activity against 46 clinical isolates of C. neoformans, with MICs ranging from 1 to 8 ÎĽg/ml, even for amphotericin B-insensitive strains. Allicin also exerted additive or synergistic effects when combined with amphotericin B and fluconazole.
Although allicin has marked antimicrobial effects, it has limited clinical applications because the minimal inhibitory concentration of allicin is relatively high. Therefore, allicin is used mainly as a supplemental agent to enhance the efficacy of chemical agents. Evidence strength: Primarily in vitro and preclinical; human clinical trials are lacking.
The antiparasitic effects of freshly crushed garlic were known by many ancient cultures. Allicin in its pure form was found to exhibit antiparasitic activity, including some major human intestinal protozoan parasites such as Entamoeba histolytica and Giardia lamblia. Research found that Entamoeba histolytica, the human intestinal protozoan parasite, is very sensitive to allicin: only 30 ÎĽg/mL of allicin totally inhibited the growth of amoeba cultures. Evidence strength: Primarily in vitro; human data is scarce.
Allicin, the most biologically active sulfur-containing compound of garlic, possesses various cardioprotective properties, including reducing blood pressure, regulating blood lipids, preventing atherosclerosis, and protecting against myocardial injury.
A randomized, double-blind, placebo trial reported that C-reactive protein, and systolic, diastolic, and mean blood pressures decreased in NAFLD patients treated with allicin 3 mg/day. According to one meta-analysis, garlic powder preparation may be useful clinically in subjects with mild hypertension. However, there is not enough data to support its use as a standard therapeutic therapy for the treatment of hypertension patients, and more well-planned and analyzed studies are required for a definitive conclusion. Evidence strength: Multiple small RCTs and meta-analyses suggest modest benefit in mild hypertension; larger, better-designed trials are still needed.
Clinical investigations have noted considerable positive changes in LDL-cholesterol level, with decreases of 11–26% frequently seen. A few trials utilizing garlic powder, which has minimal allicin yields, were unsuccessful in demonstrating any benefits on lipid levels. Another meta-analysis found no statistically significant difference between the groups receiving garlic (900 mg/day of dried garlic powder standardized to 1.3% allicin) and placebo in terms of the mean concentrations of blood lipids, lipoproteins, or apo A1 or B. Evidence strength: Mixed; some trials show modest LDL reductions, others show no effect, with results partly dependent on allicin content and preparation quality.
Clinical studies have found that allicin reduces ET-1 and C-reactive protein (CRP) levels and elevates NO levels, improves endothelial dysfunction, and reduces the incidence of restenosis in patients after percutaneous coronary intervention (PCI). In patients with coronary artery disease combined with diabetes, oral administration of allicin capsules resulted in a significant improvement in flow-mediated dilation (FMD) and NO levels, and a decline in ICAM-1 level and incidence of major adverse cardiovascular events in the allicin group compared to the control group. Evidence strength: Preliminary human clinical data; limited by study size and standardization.
Studies consistently demonstrate that allicin can induce an increase in fibrinolytic activity, inhibit platelet aggregation, improve lipid profile including reducing serum cholesterol levels, decrease blood pressure, and prevent formation of strokes. Evidence strength: Supported by multiple in vitro, animal, and some human studies, though large definitive clinical trials are lacking.
Allicin in its pure form has been found to exhibit antiviral activity, though clinical evidence in this area is less developed than for antibacterial or antifungal uses. Definitive evidence of antiviral efficacy, optimized dosing regimens, and comprehensive safety profiles for purified or formulated allicin in humans must still be established through clinical investigation. Evidence strength: Primarily in vitro; clinical human antiviral trials are very limited.
Allicin was shown to induce apoptosis, often selectively, in mammalian cancer cells cultured in vitro, in intact tissues in vivo, and in cells of yeast (Saccharomyces cerevisiae). Allicin can overcome doxorubicin resistance, cisplatin resistance, and 5-fluorouracil resistance. Allicin combined with other chemotherapy drugs showed a better anti-cancer effect.
The results of some experiments are controversial; for example, some studies of allicin and gastric cancer are inconsistent. Therefore, it is still important to explore the mechanism and progress of allicin in cancer. Evidence strength: Predominantly preclinical (in vitro and animal models); direct human clinical trial evidence for allicin specifically as an anticancer agent remains very limited. Epidemiological data linking garlic consumption to reduced cancer risk exists, but isolating the contribution of allicin is difficult.
Allicin has been extensively studied and reported for its therapeutic potential as an antioxidant with antimicrobial, anticancer, and anti-inflammatory activities. There are numerous reports on neuroprotection and improvement of cognitive abilities by the application of allicin. However, almost all study reports on these subject areas are based on preclinical studies conducted on animal models or human cell lines, and only two or three specific clinical studies have been reported.
Allicin has been described as an antioxidant and neuroprotective molecule that can ameliorate cognitive abilities in cases of neurodegenerative and neuropsychological disorders. Evidence strength: Weak for humans; predominantly animal and cell-line data; very few clinical studies.
Several studies have shown that allicin has multiple beneficial effects, including antioxidant, immunomodulatory, antidiabetic, antihypertensive, cardioprotective, and nephroprotective effects. Garlic and its components, such as organosulfur compounds, have been reported to exert positive effects on the immune system acting through several mechanisms, e.g. oxidative stress, immune and inflammatory response, and interleukins, investigated in a number of in vitro or in vivo experimental models. Evidence strength: Predominantly preclinical; human clinical evidence for specific immunomodulatory effects of allicin is limited.
By inhibiting oxidative stress and inflammation, allicin plays a hepatoprotective role in tetrachloride-induced mice, trioxide-induced rats, and lead-induced chicken models. As an adjuvant to cyclophosphamide and tamoxifen, allicin plays a beneficial role by alleviating liver injury. Some studies have also reported that allicin can improve NSAID (acetaminophen, diclofenac sodium)-induced liver injury. While these pre-clinical findings are promising, they are based on specific, induced pathologies, and the preventive or therapeutic window in humans remains undefined. Most evidence comes from rodent models and cell lines. Evidence strength: Preclinical only; no substantial human clinical trial evidence for hepatoprotection specifically from allicin.
Many in vitro and in vivo studies have reported the sulfur-containing compounds allicin and ajoene for their effective anti-diabetic, among other properties. Research in diabetic nephropathy models has concluded that allicin delays the progression of diabetic nephropathy through antioxidant and anti-inflammatory mechanisms. Evidence strength: Primarily animal and in vitro evidence; well-controlled human clinical trials of allicin specifically for diabetes or its complications remain limited.
The majority of clinical trials on the possible cardiovascular effects of garlic have used supplements standardized on alliin or allicin potential.
The bioavailability of allicin from garlic supplements and garlic foods is highly questionable and unpredictable from in vitro tests, due to dependence upon alliinase activity under conditions that challenge alliinase activity — including heat, gastric acid, and intestinal proteases. Garlic supplement manufacturing procedures and coatings, meal conditions when supplements are consumed, and garlic food preparation conditions will greatly affect allicin bioavailability.
The most common complaint after taking garlic tablets or oil is increased breath and body odor. Some also experience gastrointestinal symptoms, such as heartburn, abdominal pain, belching, nausea, vomiting, flatulence, constipation, and diarrhea.
More serious but rare side effects may include allergic reactions characterized by symptoms like rashes, itching, and difficulty breathing. Individuals with a known allergy to garlic or other Allium species should avoid allicin-containing products.
Endoscopic examination of the stomach mucosa of dogs 24 hours after the direct administration of raw garlic powder detected erosion at 15 out of 18 sites. If the garlic powder had been boiled (to inactivate the alliinase, thereby eliminating any allicin), no erosion was observed. When aged garlic extract (AGE), which contains no allicin, was administered, no erosion or redness was observed. This indicates that allicin itself, rather than garlic's non-enzymatic components, is a likely contributor to gastric mucosal irritation.
Allicin has been shown to inhibit the activity of CYP2C19, a mechanism that could potentially elevate systemic levels of co-administered antiviral drugs metabolized by this enzyme, including nelfinavir (an HIV protease inhibitor) and certain anti-hepatitis C virus agents such as dasabuvir. By contrast, allicin exhibits minimal inhibitory activity against CYP3A4, indicating a degree of enzymatic selectivity in its drug interaction profile.
People taking anticoagulant or antiplatelet drugs should exercise caution, as allicin can enhance the blood-thinning effects of these medications, increasing the risk of bleeding. Allicin may interact with medications that lower blood glucose, leading to excessive hypoglycemia. If someone is already taking antihypertensive drugs, adding garlic supplements can enhance the blood-pressure-lowering effect and further cause low blood pressure.
Allicin can affect the metabolism of certain drugs processed by the liver's cytochrome P450 enzyme system. It may alter the pharmacokinetics of drugs like statins, used for lowering cholesterol, or some chemotherapeutic agents.
The most critical step needed in the field is to transition from pre-clinical models to well-designed human clinical trials to conclusively establish efficacy, safety, and appropriate dosing for various health conditions. Substantial research investment is also needed in developing advanced formulation strategies, such as nanoparticle-based delivery systems, to overcome the challenges of stability, bioavailability, and patient compliance.
Notable progress has been made in overcoming the physicochemical limitations of allicin, particularly through the development of engineered delivery systems such as nanocarriers, which enhance stability and systemic bioavailability.
Condiciones de salud que Alicina puede ayudar a apoyar.
Allicin is the primary bioactive sulfur compound in garlic responsible for its vascular effects. It enhances NO production, inhibits ACE, and reduces arterial stiffness. Clinical evidence stems largely from garlic trials where allicin content is the active component, with demonstrated improvements in endothelial function and blood pressure.
Allicin is the primary bioactive organosulfur compound of garlic, demonstrating antifungal activity against Trichophyton rubrum—the main cause of tinea pedis—in multiple in vitro studies. Electron microscopy shows allicin causes membrane breakdown and cytoplasm disintegration in Trichophyton hyphae at 6.25–12.5 µg/ml. Clinical application is primarily through its derivative ajoene; direct RCTs for isolated allicin in tinea pedis are absent.
Allicin (diallyl thiosulfinate) is the primary bioactive organosulfur compound in garlic responsible for antiplatelet activity. It prolongs clotting time by inactivating thrombin and blocking fibrinogen-to-fibrin conversion. In vitro data show allicin-class thiosulfinates suppress human platelet aggregation and inhibit collagen-receptor platelet binding.
Allicin is the primary bioactive compound in garlic responsible for antihypertensive effects. It promotes nitric oxide production, inhibits ACE, and dilates blood vessels. Clinical evidence supporting garlic preparations' blood pressure effects is substantially attributed to allicin content.
Allicin is garlic's primary bioactive antifungal compound, with documented anti-Candida activity comparable to fluconazole in vitro. It disrupts Candida cell membranes and biofilms and inhibits hyphal transition. It is among the most well-researched natural antifungal compounds and is referenced in professional Candida protocols.
Allicin, the principal sulfur compound released from crushed garlic, demonstrates potent anti-Candida activity in vitro by suppressing fungal biofilm formation and inhibiting Candida enzymes. A 2015 clinical study found allicin-rich garlic extract tablets were approximately as effective as fluconazole for vaginal Candida infections. It is one of the most well-researched natural antifungals used in Candida cleanse protocols.
Allicin, the primary bioactive organosulfur compound in garlic, inhibits HMG-CoA reductase and reduces intestinal cholesterol absorption. Standardized allicin/ajoene extract at 600–900 mg/day showed 9–12% TC and LDL reductions in numerous placebo-controlled clinical trials.
Allicin is the primary organosulfur compound formed when garlic is crushed, responsible for most of garlic's cardiovascular and circulatory effects. It relaxes blood vessel smooth muscle, inhibits thromboxane A2, enhances NO production, and reduces platelet stickiness. Clinical evidence from garlic supplementation studies (allicin-standardised extracts) demonstrates improvements in blood flow efficiency and blood pressure.
Allicin, the primary bioactive organosulfur compound in garlic, has demonstrated antifungal activity against Candida, Cryptococcus, Trichophyton, Epidermophyton, and Microsporum species in multiple in vitro and in vivo studies. It damages fungal cell walls and membranes and disrupts biosynthesis pathways. In combination with itraconazole and terbinafine, allicin shows synergism against Microsporum canis in tinea capitis.
Allicin is the principal bioactive organosulfur compound in garlic responsible for its anti-H. pylori activity. It inhibits urease and other bacterial enzymes. In vitro studies confirm bactericidal activity against clinical H. pylori strains, and it is used in integrative protocols for H. pylori-associated gastritis.
Allicin is the primary organosulfur bioactive of garlic with potent antioxidant, antimicrobial, and cardiovascular effects relevant to aging. It generates hydrogen sulfide (H2S) in tissues — a longevity gasotransmitter — and activates Nrf2 and AMPK. Meta-analyses confirm allicin-containing garlic products reduce blood pressure and cardiovascular risk factors.
Allicin, the primary bioactive organosulfur compound of garlic, has been identified in patent literature and a systematic review as a sulfation substrate and methyl donor for homocysteine clearance, functioning similarly to TMG. A 2021 systematic review confirmed garlic extract (of which allicin is the primary active component) significantly reduced homocysteine in animal studies.
Allicin is the primary bioactive organosulfur compound from garlic demonstrating hepatoprotective effects via NLRP3 inflammasome suppression, phase II enzyme induction, and antioxidant activity. A PMC-indexed hepatoprotection review specifically documents allicin from Allium sativum as exhibiting hepatoprotective activity through suppression of NLRP3 inflammasome activation and reduction of caspase-1 and IL-1β in hepatocytes.
Allicin, the principal organosulfur compound of garlic, has been studied in bovine mammary epithelial cell (MAC-T) models of mastitis. In vitro and cell-based research shows it suppresses LPS-induced inflammation via TLR4/NF-ÎşB signaling. It also demonstrates in vitro antibacterial activity against major mastitis pathogens including Staphylococcus aureus and E. coli. Human clinical evidence is limited; most data derive from animal and cell studies.
Allicin is the primary organosulfur bioactive from crushed garlic that disrupts parasite cell membranes and energy metabolism. In vitro studies confirm activity against Giardia lamblia, Entamoeba histolytica, and Leishmania; a 2024 animal study showed enhanced activity when combined with wormwood.
Allicin, the principal organosulfur antimicrobial from garlic, has demonstrated vapor-phase killing of MDR Streptococcus pneumoniae, Pseudomonas aeruginosa, and other major lung pathogens in EUCAST-standard testing. It inhibits P. aeruginosa biofilm formation and virulence factors central to pneumonia pathogenesis. Historical records document garlic vapor inhalation for pulmonary infections in the pre-antibiotic era.
The principal antimicrobial and immunomodulatory organosulfur compound from garlic, allicin demonstrates antiviral and antibacterial properties in vitro and has been associated with reduced cold duration and incidence in clinical settings. It supports post-illness recovery through immune activation and antioxidant mechanisms.
Allicin, the active sulfur compound from garlic, is particularly effective against methane-producing microbes associated with methane-dominant SIBO (intestinal methanogen overgrowth). The 2014 Chedid et al. study included allicin-based herbal protocols that outperformed rifaximin for SIBO breath-test normalization. Stabilized allicin supplements deliver the compound directly to the small intestine, targeting gram-negative bacterial species such as E. coli, Klebsiella, and Citrobacter implicated in hydrogen-dominant SIBO.
Allicin, the principal bioactive organosulfur compound of garlic, exhibits potent antimicrobial activity against pathogens causing sinusitis and anti-inflammatory properties reducing nasal mucosal inflammation. A pharmacognosy review (rjpharmacognosy.ir, 2024) identified allicin as one of five primary bioactives validated for nasal congestion treatment. Traditional use of garlic and allicin-containing preparations for nasal and sinus ailments is extensively documented.
Allicin, the primary bioactive compound in garlic, shows well-documented antimicrobial activity against Streptococcus pyogenes and other respiratory pathogens causally linked to tonsillitis. Laboratory studies confirm its ability to inhibit a range of bacteria, viruses, and fungi. It is recognized by naturopathic practitioners as an immune-antimicrobial support compound specifically for tonsillitis.
Allicin is the main bioactive sulfur-containing compound in garlic credited with antimicrobial effects against UTI-causing bacteria including E. coli. In vitro studies demonstrate strong antibacterial activity against multiple uropathogens including antibiotic-resistant strains. By reducing uropathogen load in the urinary tract, allicin supports the ecological balance that allows beneficial Lactobacillus species to maintain urinary flora health. The VA Whole Health Library includes garlic/allicin among agents with evidence against urinary pathogens.
Allicin is the primary bioactive organosulfur compound produced when garlic is crushed or chopped, with documented antiviral activity against influenza B, HSV-1/2, rhinovirus, vaccinia, and cytomegalovirus. It acts via direct virucidal action on enveloped and non-enveloped viruses. Traditional use of garlic as an anti-infective supports its role in viral immune response.
Allicin is the principal bioactive organosulfur compound of garlic credited with its antiviral and anti-wart activity. It exhibits anti-DNA activity against HPV, enhances NK cell function, and clinical trials using garlic extract standardized for allicin content showed 70–100% wart clearance. Lipid-based formulations that preserve allicin content showed superior wart resolution compared to aqueous preparations.
Allicin is the principal antimicrobial compound in garlic and has been documented in traditional use for abscesses. In vitro studies confirm broad-spectrum antibacterial activity against Staphylococcus aureus and other abscess-causing pathogens. No dedicated clinical abscess trials exist for isolated allicin.
Allicin is the primary antimicrobial compound in garlic, generated when garlic is crushed. It provides antibacterial, antiviral, and antifungal activity against sore-throat-causing pathogens. Used traditionally as part of garlic for throat infections. Direct clinical data on isolated allicin for sore throat are limited, but its mechanism is well-characterized.
Allicin, the principal antimicrobial compound of garlic, was 'highly effective in one small trial' for cold prevention per NCCIH. It demonstrates antimicrobial and antiviral activity against influenza viruses and rhinoviruses in preclinical studies. Clinical evidence is limited to a single RCT requiring replication.
Sistemas corporales que Alicina puede ayudar a apoyar.
Volver